Frontier Medicines

Frontier Medicines is a clinical-stage precision medicine company dedicated to developing innovative therapies for genetically-defined patient populations, particularly in oncology and immunology. Founded in 2018, the company focuses on targeting disease-causing proteins that have been traditionally viewed as "undruggable." At the heart of Frontier Medicines' work is the proprietary Frontier™ Platform, which utilizes chemoproteomics, covalent chemistry, and machine learning. This platform allows for the chemical interrogation of proteins in living systems, facilitating the discovery of new drug targets. The company is committed to drug discovery and development, prioritizing high-impact oncology targets to provide meaningful benefits to patients. Frontier Medicines collaborates with global partners, including AbbVie, to explore novel therapies and expand the therapeutic potential of their platform. With a strong scientific leadership team, the company is positioned to make significant advancements in precision medicine for patients facing challenging diseases. Headquartered in South San Francisco, California, Frontier Medicines is at the forefront of next-generation drug discovery.